<ul>
<li>该计划包括组织重组、成本结构优化、外包和销售支持，以增强竞争力并支持长期战略。</li>
<li>劳动力优化措施将影响公司约 15% 的员工。</li>
<li>预计 2500 万美元的年度运营利润改善中，约 1200 万美元将在 2026 财年实现。</li>
</ul>
<p>, /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) 今天宣布其全面战略、运营和组织转型计划的第一阶段。该阶段旨在重新调整组织，以实现更明确的问责制、更严格的成本控制和更快速的执行。该计划还优化了 Accuray 的成本结构，外包部分非核心活动，同时建立内部全球卓越中心，重新分配工程资源，并更好地定位商业组织以推动销售增长和增强竞争力。一旦全面实施，该阶段预计将使运营盈利能力提高约 2500 万美元，按年化运行率计算。</p>
<p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/320376/accuray_incorporated_logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/320376/accuray_incorporated_logo.jpg"/></p>
<p>该计划的组织重组部分集中在四个主要领域：简化 Accuray 的商业结构，集中和全球化核心职能，提升全球服务和产品开发负责人直接向首席执行官汇报的地位，以及优化公司的劳动力和布局。同时，公司正在外包部分非核心活动，合理化设施，实施提高直接和间接支出效率的项目，并重新分配工程资源，以专注于高投资回报率项目和第三方解决方案的整合。这些措施将全球员工人数减少约 15%，其中薪酬和福利的节省占预计利润改善的主要部分，预计在 2026 财年实现约 1200 万美元，几乎所有举措预计将在 2026 财年末全面实施。与该计划的这一阶段相关，公司预计在 2026 财年的第二、第三和第四季度将产生约 1100 万美元的重组费用，其中大部分为现金，主要与裁员、设施整合、合同终止和其他一次性实施成本相关。Accuray 继续维持其对 2026 财年全年业绩的预测。</p>
<p>&#34;作为一个团队，我们专注于明确的公司、产品和服务战略，而第一阶段的举措是由我们在第一财季财报发布时宣布的转型领导者推动的，旨在为该战略奠定基础。这些变化使我们在全球每个地区的销售和服务更加聚焦，建立了更快、更高效的运营节奏，并创造了一个高效、更高利润的成本结构。所有这些举措将提高我们的竞争力，确保我们的团队能够在每个市场实现增长，坦率地说，使我们成为一家更好的公司。同时，我们对创新、质量、可靠性、客户满意度和患者护理的承诺仍然至关重要。通过简化我们的结构，加强问责制，并将资源与战略影响最大的领域对齐，我们更好地定位自己，继续为患者、提供者、员工和股东提供卓越价值，&#34; Accuray 首席执行官 Steve La Neve 表示。</p>
<p>Accuray 的战略贷款合作伙伴 TCW 已通知公司，他们支持公司及其战略决策，TCW 认为这些决策对加强 Accuray 未来增长的基础、利润扩张和长期成功的定位至关重要。</p>
<p>Accuray 预计将在重大进展发生时不时提供有关其转型计划的进一步更新。</p>
<p><strong>关于 Accuray</strong> Accuray 致力于扩大放射治疗的强大潜力，以改善尽可能多的生命。我们发明独特的、改变市场的解决方案，旨在为甚至最复杂的病例提供放射治疗，同时使常见可治疗病例变得更简单，以满足患者的全方位需求。我们致力于在肿瘤学、神经放射外科等领域持续创新放射治疗，与临床医生和管理人员合作，赋能他们帮助患者更快地恢复生活。Accuray 总部位于威斯康星州麦迪逊，在全球设有设施。要了解更多信息，请访问 www.accuray.com 或在 Facebook、LinkedIn、X 和 YouTube 上关注我们。</p>
<p><strong>前瞻性声明</strong> 本新闻稿中所作的非历史事实的声明为前瞻性声明，并受 1995 年《私人证券诉讼改革法案》的 “安全港” 条款的保护。本新闻稿中的前瞻性声明涉及但不限于公司的未来运营结果，包括以下预期：公司对 2026 财年全年的预测；公司执行并实现其转型计划和增长战略的能力；公司转型计划第一阶段的举措，包括时间安排和预期收益；预期的年度运营利润改善，包括 2026 财年预计的节省；预期的重组费用及其时间安排；公司的竞争力、在其运营市场中实现增长的能力，以及成为一家更好的公司的能力；以及公司为患者、提供者、员工和股东创造价值的能力。这些前瞻性声明涉及风险和不确定性。如果这些风险或不确定性中的任何一个实现，或者公司的任何假设被证明不正确，实际结果可能与这些前瞻性声明所表达或暗示的结果有重大差异。这些风险和不确定性包括但不限于公司执行其转型计划的能力；全球宏观经济环境对公司及其客户和供应商运营的影响；公司供应链的中断，包括物流成本的增加；公司实现其产品广泛市场接受度的能力；大量未偿债务及其维持与债务相关的财务契约合规性的能力；增强国际关税对公司的影响；公司实现中国合资企业及其他合作伙伴关系预期收益的能力；国际运营固有的风险；公司维持或提高产品销售和服务的毛利率的能力；监管批准或新产品开发或发布的延迟；公司满足其信贷设施下契约的能力；公司将积压订单转化为收入的能力；以及在公司于 2025 年 11 月 5 日向证券交易委员会（“SEC”）提交的 10-Q 季度报告中 “风险因素” 标题下识别的其他风险。</p>
<p>前瞻性声明仅在声明作出之日有效，并基于公司在作出这些声明时可获得的信息和/或管理层在该时刻对未来事件的善意信念。除非适用证券法律要求，否则公司不承担更新前瞻性声明以反映实际表现或结果、假设变化或影响前瞻性信息的其他因素变化的义务。因此，投资者不应对任何前瞻性声明过度依赖。</p>
<p><strong>投资者关系联系人</strong> Aman Patel, CFA</p>
<p>投资者关系，ICR Healthcare</p>
<p>aman.patel@ICRHealthcare.com</p>
<p><strong>媒体联系人</strong> Megan Brunet</p>
<p>FTI Consulting</p>
<p>Megan.brunet@fticonsulting.com</p>
<p>来源：Accuray Incorporated</p>

精确射线公司

<p>Accuray Incorporated 宣布了其战略转型计划的第一阶段，旨在提高年化运营盈利能力 2500 万美元。该计划包括组织重组、成本结构调整、外包和销售赋能。员工优化将影响 15% 的员工，预计到 2026 财年将节省 1200 万美元。公司将承担 1100 万美元的重组费用。Accuray 的战略合作伙伴 TCW 支持这些举措，旨在增强竞争力并支持长期增长</p>

<ul>
<li>Plan includes organizational realignment, rightsizing of cost structure, outsourcing, and sales enablement in order to enhance competitiveness and support long-term strategy.</li>
<li>Workforce optimization actions will affect approximately 15% of the company's employees.</li>
<li>Of the expected $25 million of annualized operating profit improvement, approximately $12 million will be realized in FY2026.</li>
</ul>
<div class="lb-trans"><ul>
<li>该计划包括组织重组、成本结构优化、外包和销售支持，以增强竞争力并支持长期战略。</li>
<li>劳动力优化措施将影响公司约 15% 的员工。</li>
<li>预计 2500 万美元的年度运营利润改善中，约 1200 万美元将在 2026 财年实现。</li>
</ul>
</div><p>, /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today announced the first phase of its comprehensive strategic, operational, and organizational transformation plan. This phase is designed to realign its organization to produce sharper accountability, tighter cost control, and faster execution. The plan also right-sizes Accuray's cost structure, outsources selected non-core activities while building internal global centers of excellence, reallocates engineering resources, and better positions the commercial organization to drive sales growth and enhance competitiveness. Once fully implemented, this phase is expected to improve operating profitability by approximately $25 million on an annualized, run-rate basis.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) 今天宣布其全面战略、运营和组织转型计划的第一阶段。该阶段旨在重新调整组织，以实现更明确的问责制、更严格的成本控制和更快速的执行。该计划还优化了 Accuray 的成本结构，外包部分非核心活动，同时建立内部全球卓越中心，重新分配工程资源，并更好地定位商业组织以推动销售增长和增强竞争力。一旦全面实施，该阶段预计将使运营盈利能力提高约 2500 万美元，按年化运行率计算。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/320376/accuray_incorporated_logo.jpg" alt="" original-src="https://mma.prnewswire.com/media/320376/accuray_incorporated_logo.jpg"/></p>
<p>The organizational realignment element of the plan focuses on four major areas: streamlining Accuray's commercial structure, centralizing and globalizing core functions, elevating the global heads of service and product development to report directly to the CEO, and optimizing the company's workforce and footprint. In parallel, the company is outsourcing selected non-core activities, rationalizing facilities, implementing programs to improve direct and indirect spend efficiency, and reallocating engineering resources to focus on high ROI programs and integration of third party solutions. These actions reduce global headcount by approximately 15%, with savings from compensation and benefits representing the majority of the expected profit improvement, of which roughly $12 million is anticipated to be realized in fiscal 2026, with virtually all initiatives expected to be fully implemented by fiscal 2026 year-end. In connection with this phase of the plan, the Company expects to incur restructuring charges in its fiscal second, third and fourth quarters totaling approximately $11 million, most of it in cash, primarily related to workforce reductions, facility consolidation, contract terminations, and other non-recurring implementation costs. Accuray continues to maintain its forecasts for full year fiscal 2026.</p>
<div class="lb-trans"><p>该计划的组织重组部分集中在四个主要领域：简化 Accuray 的商业结构，集中和全球化核心职能，提升全球服务和产品开发负责人直接向首席执行官汇报的地位，以及优化公司的劳动力和布局。同时，公司正在外包部分非核心活动，合理化设施，实施提高直接和间接支出效率的项目，并重新分配工程资源，以专注于高投资回报率项目和第三方解决方案的整合。这些措施将全球员工人数减少约 15%，其中薪酬和福利的节省占预计利润改善的主要部分，预计在 2026 财年实现约 1200 万美元，几乎所有举措预计将在 2026 财年末全面实施。与该计划的这一阶段相关，公司预计在 2026 财年的第二、第三和第四季度将产生约 1100 万美元的重组费用，其中大部分为现金，主要与裁员、设施整合、合同终止和其他一次性实施成本相关。Accuray 继续维持其对 2026 财年全年业绩的预测。</p>
</div><p>&#34;As a team, we are laser focused on a clear corporate, product and service strategy, and the phase one initiatives, which have been driven by the transformation leaders we announced at the time of our first fiscal quarter earnings release, are designed to set the stage for that strategy. The changes sharpen our focus on sales and service in every region around the world, establish a faster, more efficient operating rhythm, and create an efficient, higher-margin cost structure. All of these initiatives will increase our competitiveness, ensure our teams are poised to deliver growth in each market, and, frankly, make us a better company. At the same time, our commitment to innovation, quality, reliability, customer satisfaction, and patient care remains paramount. By simplifying our structure, strengthening accountability, and aligning resources with the areas of greatest strategic impact, we are better positioned to continue delivering exceptional value to patients, providers, employees, and shareholders,&#34; said Steve La Neve, Chief Executive Officer of Accuray.</p>
<div class="lb-trans"><p>&#34;作为一个团队，我们专注于明确的公司、产品和服务战略，而第一阶段的举措是由我们在第一财季财报发布时宣布的转型领导者推动的，旨在为该战略奠定基础。这些变化使我们在全球每个地区的销售和服务更加聚焦，建立了更快、更高效的运营节奏，并创造了一个高效、更高利润的成本结构。所有这些举措将提高我们的竞争力，确保我们的团队能够在每个市场实现增长，坦率地说，使我们成为一家更好的公司。同时，我们对创新、质量、可靠性、客户满意度和患者护理的承诺仍然至关重要。通过简化我们的结构，加强问责制，并将资源与战略影响最大的领域对齐，我们更好地定位自己，继续为患者、提供者、员工和股东提供卓越价值，&#34; Accuray 首席执行官 Steve La Neve 表示。</p>
</div><p>Accuray's strategic lending partner TCW has informed the company that they support the company and its strategic decisions, which TCW believes are essential to strengthening Accuray's foundation for future growth, margin expansion, and positioning itself for long-term success.</p>
<div class="lb-trans"><p>Accuray 的战略贷款合作伙伴 TCW 已通知公司，他们支持公司及其战略决策，TCW 认为这些决策对加强 Accuray 未来增长的基础、利润扩张和长期成功的定位至关重要。</p>
</div><p>Accuray expects to give further updates concerning its transformation plan from time to time as material developments occur.</p>
<div class="lb-trans"><p>Accuray 预计将在重大进展发生时不时提供有关其转型计划的进一步更新。</p>
</div><p><strong>About Accuray</strong> Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Madison, Wisconsin, with facilities worldwide. To learn more, visit www.accuray.com or follow us on Facebook, LinkedIn, X, and YouTube.</p>
<div class="lb-trans"><p><strong>关于 Accuray</strong> Accuray 致力于扩大放射治疗的强大潜力，以改善尽可能多的生命。我们发明独特的、改变市场的解决方案，旨在为甚至最复杂的病例提供放射治疗，同时使常见可治疗病例变得更简单，以满足患者的全方位需求。我们致力于在肿瘤学、神经放射外科等领域持续创新放射治疗，与临床医生和管理人员合作，赋能他们帮助患者更快地恢复生活。Accuray 总部位于威斯康星州麦迪逊，在全球设有设施。要了解更多信息，请访问 www.accuray.com 或在 Facebook、LinkedIn、X 和 YouTube 上关注我们。</p>
</div><p><strong>Forward-Looking Statements</strong> Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the &#34;safe harbor&#34; provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to the company's future results of operations, including expectations regarding: the company's forecasts for the full year fiscal 2026; the company's ability to execute upon and realize the benefits of its transformation plan and growth strategy; the company's first phase of its transformation plan initiatives, including timing and expected benefits; expected annualized operating profit improvement, including savings anticipated for fiscal year 2026; expected restructuring charges and timing of such charges; the company's competitiveness, ability to deliver growth in the markets in which it operates, and become a better company; and the company's ability to deliver value to patients, providers, employees, and shareholders. These forward-looking statements involve risks and uncertainties. If any of these risk or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results express or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the ability of the company to execute upon its transformation plan; the effect of the global macroeconomic environment on the operations of the company and those of its customers and suppliers; disruptions to the company's supply chain, including increased logistics costs; the company's ability to achieve widespread market acceptance of its products; substantial outstanding indebtedness and its ability to maintain compliance with financial covenants related to its debt; the effect of enhanced international tariffs on the company; the company's ability to realize the expected benefits of the China joint venture and other partnerships; risks inherent in international operations; the company's ability to maintain or increase its gross margins on product sales and services; delays in regulatory approvals or the development or release of new offerings; the company's ability to meet the covenants under its credit facilities; the company's ability to convert backlog to revenue; and such other risks identified under the heading &#34;Risk Factors&#34; in the company's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (the &#34;SEC&#34;) on November 5, 2025, and as updated periodically with the company's other filings with the SEC.</p>
<div class="lb-trans"><p><strong>前瞻性声明</strong> 本新闻稿中所作的非历史事实的声明为前瞻性声明，并受 1995 年《私人证券诉讼改革法案》的 “安全港” 条款的保护。本新闻稿中的前瞻性声明涉及但不限于公司的未来运营结果，包括以下预期：公司对 2026 财年全年的预测；公司执行并实现其转型计划和增长战略的能力；公司转型计划第一阶段的举措，包括时间安排和预期收益；预期的年度运营利润改善，包括 2026 财年预计的节省；预期的重组费用及其时间安排；公司的竞争力、在其运营市场中实现增长的能力，以及成为一家更好的公司的能力；以及公司为患者、提供者、员工和股东创造价值的能力。这些前瞻性声明涉及风险和不确定性。如果这些风险或不确定性中的任何一个实现，或者公司的任何假设被证明不正确，实际结果可能与这些前瞻性声明所表达或暗示的结果有重大差异。这些风险和不确定性包括但不限于公司执行其转型计划的能力；全球宏观经济环境对公司及其客户和供应商运营的影响；公司供应链的中断，包括物流成本的增加；公司实现其产品广泛市场接受度的能力；大量未偿债务及其维持与债务相关的财务契约合规性的能力；增强国际关税对公司的影响；公司实现中国合资企业及其他合作伙伴关系预期收益的能力；国际运营固有的风险；公司维持或提高产品销售和服务的毛利率的能力；监管批准或新产品开发或发布的延迟；公司满足其信贷设施下契约的能力；公司将积压订单转化为收入的能力；以及在公司于 2025 年 11 月 5 日向证券交易委员会（“SEC”）提交的 10-Q 季度报告中 “风险因素” 标题下识别的其他风险。</p>
</div><p>Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.</p>
<div class="lb-trans"><p>前瞻性声明仅在声明作出之日有效，并基于公司在作出这些声明时可获得的信息和/或管理层在该时刻对未来事件的善意信念。除非适用证券法律要求，否则公司不承担更新前瞻性声明以反映实际表现或结果、假设变化或影响前瞻性信息的其他因素变化的义务。因此，投资者不应对任何前瞻性声明过度依赖。</p>
</div><p><strong>Investor Relations Contact</strong> Aman Patel, CFA</p>
<div class="lb-trans"><p><strong>投资者关系联系人</strong> Aman Patel, CFA</p>
</div><p>Investor Relations, ICR Healthcare</p>
<div class="lb-trans"><p>投资者关系，ICR Healthcare</p>
</div><p>aman.patel@ICRHealthcare.com</p>
<div class="lb-trans"><p>aman.patel@ICRHealthcare.com</p>
</div><p><strong>Media Contact</strong> Megan Brunet</p>
<div class="lb-trans"><p><strong>媒体联系人</strong> Megan Brunet</p>
</div><p>FTI Consulting</p>
<div class="lb-trans"><p>FTI Consulting</p>
</div><p>Megan.brunet@fticonsulting.com</p>
<div class="lb-trans"><p>Megan.brunet@fticonsulting.com</p>
</div><p>SOURCE Accuray Incorporated</p>
<div class="lb-trans"><p>来源：Accuray Incorporated</p>
</div>

Accuray announces first phase of comprehensive strategic, operational, and organizational transformation plan; company expects first phase to improve annualized operating profitability by  approximately $25 million and set the stage for renewed growth | ARAY Stock News

精确射线公司宣布了全面战略、运营和组织转型计划的第一阶段；公司预计该阶段将使年度化运营盈利能力提高约 2500 万美元，并为重新实现增长奠定基础 | ARAY 股票新闻